Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Leukemia 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Leukemia, T-Cell 1Leukemia, Lymphoid 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × forodesine × Clear all
NCT00501735 2012-01-23

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

BioCryst Pharmaceuticals

Phase 2 Completed
144 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡